Neurodevelopmental Outcomes in Very Low Birth Weight Infants Using Aminophylline for the Treatment of Apnea  by Tey, Shu-Leei et al.
Pediatrics and Neonatology (2016) 57, 41e46Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http: / /www.pediatr -neonatol .comORIGINAL ARTICLENeurodevelopmental Outcomes in Very Low
Birth Weight Infants Using Aminophylline for
the Treatment of Apnea
Shu-Leei Tey a,b, Wei-Te Lee a, Pei-Lun Lee a, Chu-Chong Lu a,
Hsiu-Lin Chen a,c,*a Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
b Department of Pediatrics, E-da Hospital, I-Shou University, Kaohsiung, Taiwan
c Department of Respiratory Therapy, College of Medicine, Kaohsiung Medical University, Kaohsiung,
TaiwanReceived Mar 11, 2014; received in revised form Feb 26, 2015; accepted Mar 18, 2015
Available online 3 June 2015Key Words
aminophylline;
Bayley scale;
neurological
outcomes* Corresponding author. Division of N
Road, Kaohsiung City 80756, Taiwan.
E-mail address: 840062@ms.kmuh.
http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2016, Taiwan
CC BY-NC-ND license (http://creativeBackground: Aminophylline has been widely used in the treatment of apneic episodes in pre-
mature infants. Animal models suggest caution in the use of aminophylline as it may increase
the cerebral metabolic rate and decrease the rate of anoxic survival in neonates. This study
aimed to evaluate the neurological outcomes in very low birth weight (VLBW) infants treated
with aminophylline for apnea in our neonatal intensive care unit.
Methods: All VLBW infants (body birth weight < 1500 g) admitted to our neonatal intensive
care unit between January 2000 and December 2011 were enrolled in this retrospective study.
Clinical characteristics and outcomes of these infants were reviewed and recorded. Scores on
the Bayley Scales of Infant Development at 6 months, 12 months, and 18 months of corrected
age were also recorded. The controls (who did not receive aminophylline) were matched for
gestational age with the aminophylline group.
Results: The baseline characteristics of the aminophylline group and the control group were
similar. The neurodevelopmental outcomes as well as rates of patent ductus arteriosus, brain
injury, severe retinopathy of prematurity, and necrotizing enterocolitis were not significantly
different between the two groups. Only bronchopulmonary dysplasia remained significantly
higher in the aminophylline group after adjusting for risk factors (48.08% vs. 21.15%; adjusted
odds ratio: 12.50; p < 0.001).
Conclusion: Aminophylline therapy for apnea of prematurity had no apparent and additional
risk on the neurodevelopmental outcomes of VLBW infants at a corrected age of 18 months.eonatology, Department of Pediatrics, Kaohsiung Medical University Hospital, Number 100, TzYou 1st
org.tw (H.-L. Chen).
015.03.013
Pediatric Association. Published by Elsevier Taiwan LLC. This is an open access article under the
commons.org/licenses/by-nc-nd/4.0/).
42 S.-L. Tey et alFurther studies with a larger sample size are needed to confirm the adverse neurological ef-
fects of aminophylline treatment.
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open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Apnea is a common problem in preterm infants, probably
due to prematurity or an associated illness. Apnea of pre-
maturity (AOP) is found in 50% to 80% of preterm infants at
< 30 weeks of gestation, with an even higher incidence in
extremely low birth weight infants.1,2 AOP is defined as
breathing pauses that last for > 20 seconds or < 20 seconds
accompanied with bradycardia or oxygen desaturation.3,4
Such frequent hypoxic and bradycardic spells could lead
to significant decrements in brain oxygen delivery during
the critical phase of brain growth and development.5,6
Treatment for AOP includes the application of nasal
continuous positive airway pressure (NCPAP) and adminis-
tration of methylxanthines, such as aminophylline,
theophylline, and caffeine. Methylxanthines are inhibitors
of adenosine receptors; adenosine has been shown to pro-
tect the brain from energy failure and cell death during
experimental hypoxia and ischemia in animal models.7e11
Animal models suggest caution in the use of methylxan-
thines because they could increase the cerebral metabolic
rate and decrease the rate of anoxic survival in neonates.8
Whether or not methylxanthines adversely affect the neu-
rodevelopment of preterm infants is unknown.
At present, it appears that caffeine is the most effective
methylxanthine for the treatment of AOP.2,12 For instance,
one large, randomized, controlled trial on the use of
caffeine for AOP treatment found that caffeine decreases
the rates of bronchopulmonary dysplasia (BPD).13 In a
subsequent study, the authors also successfully demon-
strated that caffeine improved the rate of survival without
neurodevelopmental disabilities.14 However, data on the
outcomes of aminophylline treatment for AOP are still
scarce. Therefore, we conducted this retrospective study
to evaluate the neurodevelopmental outcomes of
aminophylline in very low birth weight (VLBW) infants
treated for AOP in our neonatal intensive care unit (NICU).
2. Methods
2.1. Study design
This was a retrospective, observational study, which used
data collected from inpatient and outpatient medical
records.
2.2. Study participants
All VLBW infants (birth body weight < 1500 g) admitted to
the NICU of Kaohsiung Medical University Hospital, Kaoh-
siung, Taiwan between January 2000 and December 2011were enrolled in this retrospective study. Clinical charac-
teristics and outcomes of the infants who received
aminophylline for the treatment of apnea during hospital-
ization were reviewed and recorded. We defined AOP as
breathing pauses that lasted for > 20 seconds or < 20
seconds accompanied with bradycardia (heart rate < 100
bpm) or oxygen desaturation. Treatment was started if an
infant had five or more apneic attacks requiring interven-
tion within 24 hours (including those in whom AOP and
NCPAP had been applied). Methylxanthine administration
was based upon the following standard regimen e an
aminophylline loading dose of 5e8 mg/kg (administered
intravenously over 30 minutes) and maintenance doses of
1.5e3 mg/kg every 8 hours to 12 hours that were adminis-
tered either intravenously or enterally. The aminophylline
dosage was adjusted to maintain a serum concentration of
5e12 mg/dL or when clinical toxicity (e.g., tachycardia,
tachypnea, or jitteriness) was noted.15 Therapy was
continued until AOP regressed. The control group
comprised infants who had AOP (< 5 apneic attacks within
24 hours or in whom AOP could be managed well with
NCPAP or tactile stimulant) but did not receive aminoph-
ylline treatment. To minimize the influence of confounding
factors between the infants with and without aminophyl-
line, we matched the groups for gestational age and then
compared the outcomes between them.
2.3. Assessment of neurodevelopmental outcomes
When the infants reached a corrected age of 6 months, 12
months, and 18 months, scores of the second version of the
Bayley Scales of Infant Development (BSID-II) for mental
and psychomotor development were evaluated.16 The
mental development index (MDI) and psychomotor devel-
opmental index (PDI) were used as scales of cognition and
motor development, respectively. Neurodevelopmental
impairment was defined as either an MDI or PDI score of <
70 (2 standard deviation below the mean of 100) on the
BSID-II. Infants were excluded if they died prior to 18
months of corrected age or if their complete BSID-II data at
6 months, 12 months, and 18 months of age were
unavailable.
2.4. Definition of neonatal variables
Patent ductus arteriosus (PDA) was defined by spontaneous
closure or therapeutic injection of a prostaglandin inhibitor
or surgical ligation. Cranial ultrasonography was performed
after hospitalization. Brain injury was defined as the pres-
ence of one of the following: (1) Grade III or higher intra-
ventricular hemorrhage (including subependymal and
intraventricular, graded according to the classification of
Aminophylline and neurodevelopmental outcomes 43Papile et al17); (2) subependymal cyst; or (3) periventricular
leukomalacia (diagnosed by cranial ultrasonography or
cranial magnetic resonance imaging). BPD was defined as
the need for supplemental oxygen support or positive
pressure support at a postmenstrual age of 36 weeks.18
Necrotizing enterocolitis (NEC) was defined as Bell’s Stage
II or greater.19,20 Severe retinopathy of prematurity (ROP)
was defined as the need for a therapeutic intervention such
as laser or cryotherapy in at least one eye.14
2.5. Statistical analysis
Categorical data are presented as n (%) and continuous data
as mean  standard deviation. The c2 test was used to
compare categorical variables, and Student t test was used
to compare continuous variables. Logistic regression was
performed to adjust for prognostically important variables
including gestational age, antenatal steroid treatment,
pregnancy-induced hypertension, prolonged ruptured
membrane, and birth body weight of the infants. JMP
version 10 (SAS Institute Inc., Cary, NC, USA) was used for
the statistical analysis. The level of statistical significance
was defined as p < 0.05.
2.6. Ethics
This study was approved by the Institutional Review Board
of Kaohsiung Medical University Hospital.
3. Results
From January 2000 to December 2011, 402 VLBW infants
(body birth weight < 1500 g) were screened for eligibility.Table 1 Characteristics of the infants and their mothers.*
Characteristics Aminophylline
(n Z 52)
Without
aminophylline
(n Z 52)
p
Mother
Age (y) 32  6 32  5 0.94
Antenatal steroid 30 (57.69) 24 (46.15) 0.24
Cesarean section 33 (63.46) 39 (75.00) 0.20
PIH 12 (23.08) 21 (40.38) 0.06
GDM 2 (3.85) 1 (1.92) 0.56
PROM (> 18 h) 16 (30.77) 19 (36.54) 0.53
Infant at birth
Birth body weight (g) 1219  202 1226  205 0.86
Gestational age (wk) 29  1 30  2 0.09
Male sex 30 (57.69) 24 (46.15) 0.24
Born at study hospital 24 (46.15) 18 (34.62) 0.23
Singleton birth 44 (84.62) 36 (69.23) 0.11
LOS (d) 73  24 68  36 0.36
Data are presented as n (%) or mean  SD.
GDM Z gestational diabetes mellitus; LOS Z length of stay;
PIH Z pregnancy-induced hypertension; PROM Z prolonged
ruptured of membrane.
* These data are for the 130 infants with adequate informa-
tion for the ascertainment of the composite primary outcome at
a corrected age of 6e18 months. Percentages may not sum to
100 because of rounding.Of these 402 VLBW infants, 84 infants (22.1%) died prior to
18 months of corrected age, and 130 infants did not have
serial evaluations of BSID-II at 6 months, 12 months, and 18
months of age. In total, 188 (46.8%) patients were deemed
eligible to participate in this study. Aminophylline was used
in 111 (59%) of these infants for the treatment of AOP. Fifty-
two gestational age-matched infants with AOP who did not
receive aminophylline were selected as the controls,
resulting in a total of 104 infants. The characteristics of the
study participants are shown in Table 1. There were no
significant differences between the baseline characteristics
of these infants in the two groups at birth and of their
mothers.
The primary outcome of this study was a composite of
PDA, brain injury, neurodevelopmental impairment at a
corrected age of 6e18 months, severe ROP, NEC, and BPD.
The rates of PDA, brain injury, neurodevelopmental
impairment, severe ROP, and NEC did not differ signifi-
cantly between the two groups (Table 2). The rate of BPD
was significantly higher in the aminophylline group (48.08%
vs. 21.15%, unadjusted odds ratio: 3.45, p < 0.005).
Because other factors may have contributed to an abnormal
neurodevelopmental outcome, we assessed the extent to
which these factors may have had a significant effect in
aminophylline treatment. We adjusted the relative risk of
the primary outcome for the confounding factors of birth
body weight, gestational age, administration of antenatal
steroid, pregnancy-induced hypertension of the mothers,
and mothers who had prolonged ruptured of membranes,
and only BPD remained a significant factor after adjustment
(adjusted odds ratio: 12.50, p < 0.001).
Seventy-nine patients (76%) had a normal score of > 70
on both the MDI and PDI, 11 patients (10.6%) had scores <
70 on both the MDI and PDI, and 14 patients (13.5%) had a
score < 70 on the PDI or MDI only at a corrected age of 12
months. The distribution of neurodevelopment outcomes at
a corrected age of 18 months was better than at a cor-
rected age of 12 months (Table 3).
There was a tendency to show that the aminophylline
group had fewer patients with scores on both the PDI and
MDI < 70 than the control group at a corrected age of 12
months (7.69% in the aminophylline group vs. 13.46% in the
control group, p Z 0.34) and at a corrected age of 18
months (3.85% in the aminophylline group vs. 11.54% in the
control group, pZ 0.14). However, these differences were
not statistically significant (Table 3). Nine infants (16.7%) in
the aminophylline group had a score < 70 on either the PDI
or MDI, which was higher than the control group (9.61%).
Most infants of these two groups had an abnormal PDI
rather than an abnormal MDI (15.38% vs. 1.92%); however,
this trend was reversed at a corrected age of 18 months
(1.92% vs. 13.46%).4. Discussion
We conducted this retrospective study in order to evaluate
the neurological outcomes of VLBW infants who received
aminophylline treatment for AOP. The results showed that
there was no significant difference in the rate of neuro-
developmental impairment between the aminophylline and
control group (at a corrected age of 6e18 months), both in
Table 2 Comparison of primary outcomes between the aminophylline group and control group.
Outcomes variable Aminophylline
(n Z 52)
Without
aminophylline
(n Z 52)
Unadjusted
odds ratio
p Adjusted odds ratio
(95% confidence interval)*
p
PDA 32 (61.54) 34 (65.38) 0.84 0.68 0.66 (0.24e1.77) 0.41
Close spontaneously 15 (28.85) 15 (28.85)
medication 12 (23.08) 11 (21.15)
PDA ligation 5 (9.62) 8 ((5.38)
Brain injuryy 19 (36.54) 22 (42.31) 0.79 0.55 0.49 (0.17e1.39) 0.19
IVH  Gr III 1 (1.92) 3 (5.77)
Subependymal cyst 19 (36.54) 22 (42.31)
PVL 2 (3.85) 6 (11.54)
Neurodevelopmental impairmentz
6 mo 11 (21.15) 13 (25.00) 0.80 0.64 0.70 (0.12e3.32) 0.66
12 mo 13 (25.00) 12 (23.08) 1.11 0.82 1.21 (0.24e6.44) 0.81
18 mo 10 (19.23) 10 (19.23) 1.00 1.00 0.73 (0.31e6.28) 0.68
Severe ROPx 1 (1.92) 1 (1.92) 1.00 1.00 0.58 (0.01e31.33) 0.77
NEC e n (%) 6 (11.54) 4 (7.69) 1.56 0.50 1.31 (0.25e7.60) 0.75
BPD en (%)jj 25 (48.08) 11 (21.15) 3.45 <0.005 12.50 (3.38e60.24) < 0.001
Data are presented as n (%).
BPD Z bronchopulmonary dysplasia; IVH Z intraventricular hemorrhage; NEC Z necrotizing enterocolitis; PDA Z patent ductus
arteriosus; PVL Z periventricular leukomalacia; ROP Z retinopathy of prematurity.
* The odds ratio has been adjusted for pregnancy-induced hypertension, gestational age, birth body weight, presence or absence of
antenatal administration of steroids, and prolonged ruptured membrane (> 18 hours).
y This outcome is for the infants who underwent cranial ultrasonography at least once during hospitalization.
z Neurodevelopmental impairment was defined as either a Mental Developmental Index score or Psychomotor Developmental Index
score < 70.
x Severe retinopathy of prematurity was defined as unilateral or bilateral disease of stage 4 or 5. Infants were also classified as having
severe retinopathy if they received cryotherapy or laser therapy in at least one eye.
jj Bronchopulmonary dysplasia was defined by the use of supplementary oxygen or positive pressure support at a postmenstrual age of
36 weeks.
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factors. This result suggests that aminophylline did not
adversely affect the neurodevelopment of VLBW preterm
infants at a corrected age of 6e18 months. These results
are in contrast with those in the study of Davis et al,21
whose observational study showed an association between
neonatal exposure to theophylline and cerebral palsy at 14
years of age in a cohort of VLBW children. Since the study
by Davis et al21 was published in 2000, this difference can
probably be explained by the fact that the care of VLBW
premature infants in NICUs has since advanced, including
the strategies of gentle ventilation and an improvement ofTable 3 Distribution of MDI and PDI scores between the amin
months and 18 months.
At a corrected age of 12 mo
Aminophylline
(n Z 52)
Without aminophyllin
(n Z 52)
Both PDI & MDI < 70 4 (7.69) 7 (13.46)
Either PDI or MDI < 70 9 (16.7) 5 (9.61)
Only MDI <70 1 (1.92) 0 (0)
Only PDI <70 8 (15.38) 5 (9.62)
Data are presented as n (%).
MDI Z mental developmental index; PDI Z psychomotor developmenthe mechanical ventilator. Additionally, many factors were
proposed to exert influences on neurodevelopmental out-
comes in later life of VLBW infants. For instance, Ghods
et al22 reported a close relationship between head
circumference growth and neurodevelopmental outcomes.
Their data showed that head circumference catch-up and
developmental scores were prominently affected by being
born to married families, to mothers with a higher educa-
tion level, being the first born, as well as having a strong
financial situation, and good home facilities. The neuro-
developmental outcomes at 18 months in our study may not
accurately predict neurological function later in childhood.ophylline group and control group at a corrected age of 12
At a corrected age of 18 mo
e p Aminophylline
(n Z 52)
Without aminophylline
(n Z 52)
p
0.34 2 (3.85) 6 (11.54) 0.14
0.82 8 (15.38) 4 (7.69) 0.22
0.31 7 (13.46) 4 (7.69) 0.34
0.38 1 (1.92) 0 (0) 0.31
tal index.
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may provide additional information that could enable cli-
nicians to detect long-term consequences of aminophylline
therapy.
Caffeine is another methylxanthine that is commonly
prescribed to prevent or to treat apnea of preterm infants
in Europe and the United States. Schmidt et al13,14 reported
that caffeine therapy for AOP improved the rate of BPD and
survival without neurodevelopmental disabilities at 18e21
months in VLBW infants, which suggests that caffeine is a
more effective methylxanthine for the treatment of AOP.
However, intravenous aminophylline is widely used in NICUs
for the treatment of AOP in Taiwan due to the lack of
intravenous caffeine. There have been few clinical reports
on the efficacy of aminophylline for BPD prevention or
treatment. The pathologic changes in BPD result in
increased airway resistance,23 decreased number of
alveoli, and increased airspace.24 Rooklin et al25 have sug-
gested that theophylline may play a role in decreasing
airway resistance, increasing dynamics compliance, and
shortening the duration of ventilator weaning of infants
aged < 30 days with BPD. He et al24 have also proposed that
theophylline may protect against BPD by regulating the
balance between pro- and anti-inflammatory cytokine
expression. Our results showed that the rate of BPD was
significantly higher in the aminophylline group and
remained significantly different between the two groups
even after adjusting for other risk factors. Based on these
results, we speculated that the infants with severe AOP
might need longer NCPAP support combined with
aminophylline treatment. The incidence of BPD may thus
be higher in the aminophylline group because we defined
BPD as the need for supplemental oxygen support or posi-
tive pressure support at a postmenstrual age of 36 weeks.
Aminophylline treatment is thought to be a therapeutic
strategy for AOP and BPD.23,24,26 Considering this, we
speculated that the high percentage of BPD in the
aminophylline group was because these infants had more
severe and longer AOP, and consequently they needed
longer NCPAP support combined with aminophylline treat-
ment to prevent hypoxic insult to the brain. According to
our NICU policy, NCPAP and aminophylline for the treat-
ment of AOP are preferable to a high oxygen concentration
supplement.
The use of methylxanthines has been reported to be a
risk factor for NEC.13,27,28 Erenberg et al29 designed a study
enrolling a total of 85 infants randomly assigned to either a
caffeine group or a placebo group, and they reported that
four patients had NEC in the caffeine group and two pa-
tients had NEC in the placebo group. Our results showed
that the rate of NEC was not different between those who
did and did not receive aminophylline.
In addition, we showed that aminophylline treatment
resulted in both PDI and MDI impairment at a corrected age
of 12 months and 18 months compared with those who did
not receive aminophylline. However, these data showed no
statistically significant correlation between aminophylline
treatment and neurologic outcome at 12 months and 18
months of corrected age. This implies that aminophylline
treatment is not the main factor causing neuro-
developmental impairment in infants with AOP. We also
observed that most of those treated with aminophylline hadan abnormal PDI rather than an abnormal MDI at a cor-
rected age of 12 months, although PDI improved at a cor-
rected age of 18 months. We speculate that this reduction
may be related to other specific or general developmental
programs, such as occupational or physical therapy. Addi-
tional studies are warranted to establish the effect of
rehabilitation on PDI.30
There are several limitations to this study. The major
limitation is the retrospective design, as it is very difficult
to determine from a retrospective study whether
aminophylline adversely affected the neurodevelopmental
outcomes of the VLBW infants. However, this issue was
addressed by matching a control group for gestational age
and adjusting for relative risk factors in this study. The
disease severity of AOP was different in these two groups
based on the clinical situation in this retrospective study.
With concerns over adverse effects on the neuro-
development of preterm infants with frequent AOP, using
aminophylline to treat AOP is necessary for infants in
aminophylline group. However, aminophylline in the
treatment of AOP may adversely affect the neurological
outcome based on animal studies. Our data showed that the
neurological outcome in the aminophylline group was not
poorer than the control group after adjusting for relative
risk factors, although there were different disease sever-
ities of AOP in these two groups. Another limitation is the
exclusion of 40.8% surviving infants who did not receive
complete BSID-II evaluations. These infants had a higher
gestational age and a lower BPD rate than the aminophyl-
line group. We cannot exclude the possibility that the
exclusion of these infants may have led to a slight over-
estimation of the overall outcomes. In addition, our sample
size was relatively small and from a single medical center.5. Conclusion
In conclusion, aminophylline treatment for AOP did not
adversely affect the neurological outcomes of the VLBW
infants at a corrected age of 18 months in this study. Larger
trials are needed to confirm our results with regards to the
safety of aminophylline for the treatment of apnea. A
longer follow-up period is also needed to investigate the
long-term outcomes of aminophylline therapy.Conflicts of interest
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